CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 140 enrolled
Drug / intervention
RVL-1201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02436759
NCT02436759Phase 3Completed
CompareCT.gov

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

RVL Pharmaceuticals, Inc.·interventional·Posted May 7, 2015·Updated Oct 28, 2021

In Brief

A Phase 3 clinical trial evaluating RVL-1201 and RVL-1201 Vehicle Placebo for Acquired Blepharoptosis. Completed, enrolled 140 participants across 14 sites.

Detailed Summary

This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcquired Blepharoptosis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 7, 2015
Enrollment StartMay 1, 2015
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.2 years ago

Interventions

RVL-1201drug

RVL-1201 Ophthalmic Solution 0.1%

RVL-1201 Vehicle Placebodrug

RVL-1201 Vehicle Placebo